Heart failure and chronic obstructive pulmonary disease

Czech version

Authors: Pudil R.
Authors‘ workplace: . interní kardioangiologická klinika LF UK a FN Hradec Králové ¹
Published in: Kardiol Rev Int Med 2019, 21(3): 117-120

Overview

The simultaneous incidence of chronic obstructive pulmonary disease and heart failure is not uncommon and significantly increases the mortality of these patients. Therefore, an early diagnosis and the choice of optimal therapy are important. Diagnostics can be difficult sometimes; both conditions have certain symptoms in common. When interpreting the results of certain examination methods, it is necessary to take into account the possibility of interaction (natriuretic peptides, functional examination of the lungs). The choice of optimal therapy is of great importance, but may have some pitfalls (e. g. high doses of beta-agonists in high-risk cardiovascular patients, or under-titration/ withdrawal of beta-blockers). The therapy for both diseases requires the cooperation and mutual awareness of the cardiologist and the pulmonologist.

Keywords:

therapy – SGLT2 – chronic obstructive pulmonary disease – diagnostics

Sources

1. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(27): 2129–2200. doi: 10.1093/ eurheartj/ ehw128.

2. Špinar J, Hradec J, Špinarová L et al. Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of Cardiology. Cor Vasa 2018; 58: e530–e568. doi: 10.1016/ j.crvasa.2016.09.004.

3. Koblížek V, Zatloukal J, Konštacký S. Chronická obstrukční plicní nemoc. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Dostupné na: https:/ / www.svl.cz/ files/ files/ Doporucene-postupy/ 2017/ DP-CHOPN-2019.pdf.

4. Hawkins NM, Petrie MC, Jhund PS et al. Heart failure and chronic obstructive pulmonary disease: diag-nostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11(2): 130–139. doi: 10.1093/ eurjhf/ hfn013.

5. Hawkins NM, Petrie MC, Macdonald MR et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. J Am Coll Cardiol 2011; 57(21): 2127–2138. doi: 10.1016/ j.jacc.2011.02.020.

6. Rusinaru D, Saaidi I, Godard S et al. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol 2008; 101(3): 353–358. doi: 10.1016/ j.amjcard.2007.08.046.

7. Boudestein LC, Rutten FH, Cramer MJ et al. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009; 11(12): 1182–1188. doi: 10.1093/ eurjhf/ hfp148.

8. Boschetto P, Beghe B, Fabbri LM et al. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology 2012; 17(3): 422–431. doi: 10.1111/ j.1440-1843.2011.02118.x.

9. Magnussen H, Canepa M, Zambito PE et al. What can we learn from pulmonary function testing in heart failure? Eur J Heart Fail 2017; 19(10): 1222–1229. doi: 10.1002/ ejhf.946.

10. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J 2013; 34(36): 2795–2803. doi: 10.1093/ eurheartj/ eht192.

11. Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2019. Available at: https:/ / goldcopd.org.

12. Huerta C, Lanes SF, Garcia Rodriguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005; 16(3): 360–366. doi: 10.1097/ 01.ede.0000158743.90664.a7.

13. Van der Hooft CS, Heeringa J, Brusselle GG et al.Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006; 166(9): 1016–1020. doi: 10.1001/ archinte.166.9.1016.

14. Brook RD, Anderson JA, Calverley PM et al. Cardiovascular outcomes with an inhaled beta2-agonist/ corticosteroid in patients with COPD at high cardiovascular risk. Heart 2017; 103(19): 1536–1542. doi: 10.1136/ heartjnl-2016-310897.

15. Rottenkolber M, Rottenkolber D, Fischer R et al.Inhaled beta-2-agonists/ muscarinic antagonists and acute myocardial infarction in COPD patients. Respir Med 2014; 108(8): 1075–1090. doi: 10.1016/ j.rmed.2014.05.014.

16. White WB, Cooke GE, Kowey PR et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 2013; 144(3): 758–765. doi: 10.1378/ chest.12-2332.

17. Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 1990; 98(3): 672–678. doi: 10.1378/ chest.98.3.672.

18. Gershon A, Croxford R, Calzavara A et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013; 173(13): 1175–1185. doi: 10.1001/ jamainternmed.2013.1016.

19. Rogliani P, Matera MG, Ora J et al. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chron Obstruct Pulmon Dis 2017; 12: 3469–3485. doi: 10.2147/ COPD.S146338.

20. Lipworth B, Skinner D, Devereux G et al. Underuse of b-blockers in heart failure and chronic obstructive pulmonary disease. Heart 2016; 102(23): 1909–1914. doi: 10.1136/ heartjnl-2016-309458.

21. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselec-tive beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137(9): 715–725. doi: 10.7326/ 0003-4819-137-9-200211050-00035.

22. Rutten FH, Zuithoff NP, Hak E et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170(10): 880–887. doi: 10.1001/ archinternmed.2010.112.

23. Trinkmann F, Saur J, Borggrefe M et al. Cardiovascular comorbidities in chronic obstructive pulmonary disease (COPD) – Current Considerations for Clinical Practice. J Clin Med 2019; 8(1): pii: E69. doi: 10.3390/ jcm8010069.